Sunday, November 22, 2026
English edition

Development

FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

November 10, 2026 Development Source: Ars Technica

FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

Share this article

After that study, other researchers began digging into more data, conducting meta-analyses, mining databases, and running observational studies to assess the potential link. Overall, the results were mixed. Some studies found no link, or only found links in specific comparisons, while others backed up the association. For instance, a meta-analysis of 78 randomized controlled trials found that semaglutide did not increase the risk of eye disorders generally, but did increase the risk of NAION. However, the finding was based on just five trials that specifically reported NAION events. Another study that used an electronic health records database looked at 37.1 million patients with diabetes. It found that semaglutide generally wasn’t linked to NAION. The study only saw an increased risk in a very specific analysis: When patients taking semaglutide were compared to patients taking one specific anti-diabetes drug (empagliflozin)—which was one of three comparator drugs in the study—and only when the researchers used a specific definition for NAION cases that included having a confirmatory diagnostic code in the patients’ records. In the announcement Monday, the FDA reported it had conducted its own meta-analysis, which included 126 trials that collectively contained data on over 130,000 patients. From there, the FDA identified 15 probable NAION cases: 10 in patients taking a GLP-1 drug, five in patients who received a placebo, and none in patients on non-GLP-1 drugs. The agency also did a retrospective cohort study of patients with type 2 diabetes who took a GLP-1 or one of two common diabetes medications between 2019 and 2024. The non-GLP-1 drugs were either a sodium glucose co-transporter-2 (SGLT-2) inhibitor or a dipeptidyl peptidase-4 (DPP-4) inhibitor. The agency found no increased risk of NAION in patients taking a GLP-1 compared to those taking an SGLT-2, but there was an increased risk compared to those taking DPP-4. The FDA’s statement has a more flexible recommendation, advising healthcare providers to “consider discontinuing the GLP-1 RA in patients who develop NAION, unless the benefits of treatment clearly outweigh the risk.” That recommendation echoes the recommendation from the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society. In May, the two groups published a joint consensus statement that recommended “shared decision-making between the patient and their care team” on whether to start, continue, or discontinue taking a GLP-1 drug if NAION develops or if a patient is at higher risk. In an emailed statement to Ars Technica, the American Academy of Ophthalmology said its recommendation has not changed with any new data since May and that the FDA’s stance is “broadly consistent with the conclusions of the joint statement” from May. The academy holds that “there may be an association between GLP-1 [receptor agonist] use and NAION, but NAION remains rare, any increase in absolute risk appears small, and causation has not been established.” The organization also highlighted that the FDA’s warning spans across the class of GLP-1 drugs, while most of the studies so far have focused on semaglutide. “Data for individual GLP-1 medications other than semaglutide remain more limited, and whether any association differs among individual agents or patient populations remains uncertain,” the academy wrote. The ophthalmologists again emphasized shared decision-making between patients who develop NAION and their care providers. “GLP-1 medications can provide important benefits for patients with diabetes, obesity, and cardiovascular disease, and the benefits and risks of stopping treatment may differ substantially from patient to patient. The decision to continue or discontinue treatment should therefore be made with the patient’s care team, taking into account the indication for treatment, overall health, alternative therapeutic options, and the potential risk to the fellow eye.”